Education
About Us
Working with TipRanks
Follow Us
Celcuity (CELC)
NASDAQ:CELC
CELC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.58 - $53.40
Previous CloseN/A
Volume14.25K
Average Volume (3M)1.89M
Market Cap
$2.04B
Enterprise Value$424.07M
Total Cash (Recent Filing)$205.69M
Total Debt (Recent Filing)$98.71M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Nov 17, 2025EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding40,751,050
10 Day Avg. Volume1,224,869
30 Day Avg. Volume1,892,498
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-13.63K
Enterprise Value/Ebitda-3.61
Forecast
1Y Price Target
$59.00Price Target Upside13.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Efficacy ResultsCelcuity's triplet therapy shows best-in-category efficacy with a significant increase in progression-free survival compared to existing treatments.
Regulatory ApprovalPositive topline results from the PIK3CA wild-type cohort of the pivotal VIKTORIA-1 study significantly increase the likelihood of FDA approval for gedatolisib.
Safety ProfileThe improved safety profile in the Phase 3 study, with a lower discontinuation rate and reduced side effects, contributes positively to the overall assessment of the drug's potential.
Bears Say
Censoring On Kaplan Meier CurvesThe level of censoring on the Kaplan Meier curves appears higher than expected, making it difficult to fully understand the extent of the censoring.
Control Arm PerformanceThe control arm of fulvestrant monotherapy may have underperformed, as the mPFS was expected to be around 3.5 months, but was only 2 months.
Treatment DiscontinuationsSafety data was sparse in the topline, but management indicated that the profile was better than that seen in the Ph1b, with lower discontinuation rates, hyperglycemia, and stomatitis.
Celcuity News
CELC FAQ
What was Celcuity’s price range in the past 12 months?
Celcuity lowest stock price was $7.58 and its highest was $53.40 in the past 12 months.
What is Celcuity’s market cap?
Celcuity’s market cap is $2.04B.
When is Celcuity’s upcoming earnings report date?
Celcuity’s upcoming earnings report date is Nov 17, 2025 which is in 93 days.
How were Celcuity’s earnings last quarter?
Celcuity released its earnings results on Aug 14, 2025. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of -$0.884 by -$0.156.
Is Celcuity overvalued?
According to Wall Street analysts Celcuity’s price is currently Undervalued.
Does Celcuity pay dividends?
Celcuity does not currently pay dividends.
What is Celcuity’s EPS estimate?
Celcuity’s EPS estimate is -1.01.
How many shares outstanding does Celcuity have?
Celcuity has 40,751,050 shares outstanding.
What happened to Celcuity’s price movement after its last earnings report?
Celcuity reported an EPS of -$1.04 in its last earnings report, missing expectations of -$0.884. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Celcuity?
Currently, no hedge funds are holding shares in CELC
Celcuity Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.00 (13.70% Upside)
$59.00 (13.70% Upside)
Blogger Sentiment
Bullish
CELC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 24.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▲ 89.1%
Last 30 Days ▲ 89.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
217.75%
12-Months-Change
Fundamentals
Return on Equity
-115.39%
Trailing 12-Months
Asset Growth
15.91%
Trailing 12-Months
Company Description
Celcuity
Celcuity Inc. is a biotechnology company focused on discovering new cancer sub-types and developing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. Operating primarily within the healthcare sector, Celcuity’s core product, CELsignia, is a platform that identifies the dynamic cellular activity in a patient's cancerous cells, helping to determine the most effective targeted therapy for their treatment.
CELC Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mix of positive developments in clinical trials and potential market opportunities, contrasted by increased financial losses and operational cash burn. The anticipation for upcoming data readouts is high, but there are concerns about financial sustainability.View all CELC earnings summariesCELC Stock 12 Month Forecast
Average Price Target
$59.00
▲(13.70% Upside)
Technical Analysis
Altimmune
―
Autolus Therapeutics
―
Oric Pharmaceuticals
―
Abivax SA Sponsored ADR
―
Rapport Therapeutics, Inc.
―
Ownership Overview
12.27% Insiders
12.43% Mutual Funds
0.15% Other Institutional Investors
67.09% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---